For the first time in nearly 50 years, the U.S. Food and Drug Administration will examine asbestos testing for talc powders and cosmetics at a hearing.
Over the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
An injection to treat forehead wrinkles is set to rival Allergan plc’s Botox after U.S. regulators approved Evolus Inc.’s cheaper treatment, sending the Newport Beach, Calif.-based company’s shares up about 5 percent.
Revance Therapeutics Inc. will wait to seek partnerships with bigger drugmakers until the company is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.
Allergan Plc, best known as the maker of Botox, announced today that it will buy Kythera Biopharmaceuticals, Inc. (KYTH) for approximately $2.1 billion. Kythera is focused on treatments for double chins and male pattern baldness. The deal for the Dublin-based Allergan Inc. (AGN) to pay about $75 per Kythera share. About 80 percent will be […]
One thing about Allergan chief executive Brent Saunders is he doesn’t waste much time. After all, he was personally involved in setting up $97 billion worth of deals last year. The $66 billion acquisition of the company that used to be called Allergan by Saunders’ outfit, then called Actavis, closed in March. On Monday, Actavis changed its […]